Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Income (2016 - 2025)

Historic Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • Per Theravance Biopharma's latest filing, its Net Income stood at $3.6 million for Q3 2025, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • Theravance Biopharma's Net Income's 5-year high stood at $927.1 million during Q3 2022, with a 5-year trough of -$23.1 million in Q4 2024.
  • Moreover, its 5-year median value for Net Income was $3.6 million (2025), whereas its average is $50.3 million.
  • As far as peak fluctuations go, Theravance Biopharma's Net Income skyrocketed by 440000.49% in 2022, and later crashed by 31854.13% in 2023.
  • Over the past 5 years, Theravance Biopharma's Net Income (Quarter) stood at $25.8 million in 2021, then crashed by 84.9% to $3.9 million in 2022, then crashed by 318.54% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then skyrocketed by 115.65% to $3.6 million in 2025.
  • Its Net Income was $3.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$13.5 million in Q1 2025.